Amgen, Genentech Await Del. Ruling In Biosimilar IP Row
Law360, Los Angeles (January 11, 2018, 6:13 PM EST) -- A California federal judge on Thursday tentatively paused Amgen's suit seeking to invalidate more than two dozen patents related to Genentech's cancer treatment Avastin, saying he wanted to see whether a Delaware court will transfer infringement actions that Genentech has filed over Amgen's biosimilar version of the drug.
U.S. District Court Judge George Wu held a hearing on Genentech's motion to dismiss Amgen's suit seeking a declaration that 27 patents related to Avastin are invalid, unenforceable and not infringed by Amgen's biologic, which has been approved by the U.S. Food and Drug Administration.
Genentech has filed two suits in Delaware that accuse...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!